The Effect of Thiamine, Ascorbic Acid, and the Combination of Them on the Levels of Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) in Sepsis Patients

References

• Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis. 2017;9(4):943–945. doi:10.21037/jtd.2017.03.125
   PubMed Web of Science ®Google Scholar
• Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7
   PubMed Web of Science ®Google Scholar
• Neligan P. Anaesthesia and Uncommon Disease. 5th Infectious Disease and Bioterrorism ed. United States of America: Philadhelpia: Saunder Elsevier; 2006:377–411. doi:10.1016/B978-141602212-1.50015-9
   Google Scholar
• Rhee C, Klompas M. Sepsis trends: increasing incidence and decreasing mortality, or changing denominator? J Thorac Dis. 2020;12(Suppl 1):S89. doi:10.21037/jtd.2019.12.51
   PubMed Web of Science ®Google Scholar
• Knoop S, Skrede S, Langeland N, Flaatten H, Brakenridge S. Epidemiology and impact on all-cause mortality of sepsis in Norwegian hospitals: a national retrospective study. PLoS One. 2017;12(11):e0187990. doi:10.1371/journal.pone.0187990
   PubMed Web of Science ®Google Scholar
• Vandooren J, Swinnen W, Ugarte-Berzal E, et al. Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1. Haematologica. 2017;102(10):1671–1682. doi:10.3324/haematol.2017.168799
   Web of Science ®Google Scholar
• Galliera E, Tacchini L, Corsi Romanelli MM. Matrix metalloproteinases as biomarkers of disease: updates and new insights. Clinical Chemistry and Laboratory Medicine. Walter de Gruyter GmbH. 2015;53:349–355. doi:10.1515/cclm-2014-0520
   Web of Science ®Google Scholar
• Lorente L, Martín MM, Labarta L, et al. Matrix metalloproteinase-9, −10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009;13(5):1–9. doi:10.1186/cc8115
   Web of Science ®Google Scholar
• Lorente L, Martín MM, Solé-Vioĺn J, et al. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. PLoS One. 2014;9(4):e94318. doi:10.1371/journal.pone.0094318
   Web of Science ®Google Scholar
• Bojic S, Kotur-Stevuljevic J, Kalezic N, et al. Diagnostic value of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis-associated acute kidney injury. Tohoku J Exp Med. 2015;237(2):103–109. doi:10.1620/tjem.237.103
   Web of Science ®Google Scholar
• Serrano-Gomez S, Burgos-Angulo G, Niño-Vargas DC, et al. Predictive Value of Matrix Metalloproteinases and Their Inhibitors for Mortality in Septic Patients: a Cohort Study. J Intensive Care Med. 2020;35:95–103. doi:10.1177/0885066617732284
   Web of Science ®Google Scholar
• Moskowitz A, Andersen LW, Huang DT, et al. Ascorbic acid, corticosteroids, and thiamine in sepsis: a review of the biologic rationale and the present state of clinical evaluation. Critical Care BioMed Central Ltd. 2018;22:548. doi:10.1186/s13054-018-2217-4
   Web of Science ®Google Scholar
• Donnino MW, Carney E, Cocchi MN, et al. Thiamine deficiency in critically ill patients with sepsis. J Crit Care. 2010;25(4):576–581. doi:10.1016/j.jcrc.2010.03.003
   Web of Science ®Google Scholar
• Marik PE, Khangoora V, Rivera R, Hooper MH. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: a Retrospective Before-After Study. Chest. 2017;151(6):1229–1238. doi:10.1016/j.chest.2016.11.036
   PubMed Web of Science ®Google Scholar
• Fujii T, Luethi N, Young PJ, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support among Patients with Septic Shock: the VITAMINS Randomized Clinical Trial. JAMA. 2020;323(5):423–431. doi:10.1001/jama.2019.22176
   PubMed Web of Science ®Google Scholar
• Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice. Int J Oncol. 2013;42(1):55–64. doi:10.3892/ijo.2012.1712
   PubMed Web of Science ®Google Scholar
• Tarallo S, Beltramo E, Berrone E, Dentelli P, Porta M. Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol. 2010;47(2):105–111. doi:10.1007/s00592-009-0124-5
   Web of Science ®Google Scholar
• Nagaset H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–21494. doi:10.1074/jbc.274.31.21491
   Web of Science ®Google Scholar
• Opdenakker G, Van Den Steen PE, Van Damme J, Gelatinase B. A tuner and amplifier of immune functions. Trends Immunol. 2001;22:571–579. doi:10.1016/S1471-4906(01)02023-3
   PubMed Web of Science ®Google Scholar
• Maitra SR, Shapiro MJ, Bhaduri S, El-Maghrabi MR. Effect of chemically modified tetracycline on transforming growth factor-β1 and caspase-3 activation in liver of septic rats. Crit Care Med. 2005;33(7):1577–1581. doi:10.1097/01.CCM.0000169880.82060.F7
   Web of Science ®Google Scholar
• Takeshita S, Tokutomi T, Kawase H, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol. 2001;125(2):340. doi:10.1046/j.1365-2249.2001.01608.x
   Web of Science ®Google Scholar
• Maitra SR, Jacob A, Zhou M, Wang P. Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int J Clin Exp Med. 2010;3(3):180–185.
   Web of Science ®Google Scholar
• Hoffmann U, Bertsch T, Dvortsak E, et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis. 2006;38(10):867–872. doi:10.1080/00365540600702058
   PubMed Web of Science ®Google Scholar
• Lalu MM, Cena J, Chowdhury R, Lam A, Schulz R. Matrix metalloproteinases contribute to endotoxin and interleukin-1β induced vascular dysfunction. Br J Pharmacol. 2006;149(1):31–42. doi:10.1038/sj.bjp.0706823
   Web of Science ®Google Scholar
• Maitra SR, Bhaduri S, Valane PD, Tervahartiala T, Sorsa T, Ramamurthy N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock. 2003;20(3):280–285. doi:10.1097/00024382-200309000-00014
   Web of Science ®Google Scholar
• Sivula M, Hästbacka J, Kuitunen A, et al. Systemic matrix metalloproteinase-8 and tissue inhibitor of metalloproteinases-1 levels in severe sepsis-associated coagulopathy. Acta Anaesthesiol Scand. 2015;59(2):176–184. doi:10.1111/aas.12423
   Web of Science ®Google Scholar
• Wohlschlaeger J, Stubbe HD, Schmitz KJ, et al. Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model. Pathol Res Pract. 2005;201(12):809–817. doi:10.1016/j.prp.2005.08.009
   Web of Science ®Google Scholar
• Lalu MM, Gao CQ, Schulz R. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol Cell Biochem. 2003;251(1–2):61–66. doi:10.1023/A:1025417529167
   Web of Science ®Google Scholar
• Biswas MHU, Almeida S, Lopez-Gonzalez R, et al. MMP-9 and MMP-2 Contribute to Neuronal Cell Death in iPSC Models of Frontotemporal Dementia with MAPT Mutations. Stem Cell Rep. 2016;7(3):316–324. doi:10.1016/j.stemcr.2016.08.006
   Web of Science ®Google Scholar
• Chen Y, Wang W, Liu F, Tang L, Tang R, Li W. Apoptotic effect of matrix metalloproteinases 9 in the development of diabetic retinopathy. Int J Clin Exp Pathol. 2015;8(9):10452–10459.
   Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839. doi:10.1161/01.RES.0000070112.80711.3D
   PubMed Web of Science ®Google Scholar
• Iglesias J, Vassallo AV, Patel VV, Sullivan JB, Cavanaugh J, Elbaga Y. Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis: the ORANGES Trial. Chest. 2020;158(1):164–173. doi:10.1016/j.chest.2020.02.049
   PubMed Web of Science ®Google Scholar